HALIFAX, Feb. 21, 2019 /CNW/ – Adaptiiv Medical Technologies Inc. (Adaptiiv) is pleased to announce that the Centre Hospitalier de l’Université de Montréal (CHUM) has become its latest collaboration partner. The two organizations have agreed to work together to design, develop, and validate a new solution for surface and intracavitary brachytherapy within Adaptiiv’s 3D Bolus Software.
Seamless Integration Into Existing Workflows
“Adaptiiv is the first company to offer a platform that fully integrates into the existing treatment workflow and their team has demonstrated the ability to rapidly develop and validate new ideas that can be used in treatment today. The opportunity to work in consultation with Adaptiiv to develop and showcase new brachytherapy applications can lead to tremendous breakthroughs in radiation therapy,” says François DeBlois, Physics Department Head, Radiation Oncology at CHUM.
We are shaping the future of patient-specific healthcare through innovation and collaboration with leading cancer centers throughout the world. Now that 3D printing is becoming widely adopted and clinically accepted, our solution allows clinics to 3D print patient-specific devices for use in radiation therapy. We are the world’s first company to receive U.S. FDA 510(k) clearance to market 3D printing software for use in radiation oncology, are ISO 13485 certified, and have received a CE Mark.